HPV vaccine could reduce cervical cancer

The new HPV vaccine, Gardasil 9, could reduce cervical cancer incidence and mortality if adopted widely across the United States, according to a study by Yale researchers led by David P. Durham, Ph.D., associate research scientist in epidemiology. HPV is the most common sexually transmitted infection in the country and the primary cause of cervical cancer. The study, published in Proceedings of the National Academy of Sciences—which considered 10 types of HPV, demographics of each state, age, sexual behavior, and state-specific vaccine policy—found that the new vaccine could reduce cervical cancer incidence by 73 percent, compared to 63 percent with the old vaccine. It could also reduce mortality by 49 percent versus 43 percent. And, the analysis showed, the cost would be the same as or less than that of the old vaccine. Study authors suggest that states could benefit if they all got on board for a uniform vaccination policy, since people often move between states. The authors also showed that the most cost-efficient way to implement the vaccine is to increase funding to the states with low coverage.


Other Roundup


Cell phones, earthquakes, and mental health

Cell phones, earthquakes, and mental health

When earthquakes and tsunamis strike in Asia, there are few resources to treat the resulting...

Read more...


A chemical tweak to the genome

A chemical tweak to the genome

For the past 40 years, biologists have been searching for something they weren’t sure even...

Read more...


Cancer and the chaos of lupus

Antibodies in lupus patients are the culprits of chaos—they cause the patient’s immune system to...

Read more...

Download on the Apple App Store